tiprankstipranks
Trending News
More News >
IN8bio (INAB)
NASDAQ:INAB

IN8bio (INAB) AI Stock Analysis

Compare
319 Followers

Top Page

IN

IN8bio

(NASDAQ:INAB)

Rating:34Underperform
Price Target:
IN8bio's stock score reflects significant financial challenges, typical of early-stage biotechnology companies. The financial performance is hindered by substantial operational losses and reliance on external funding, while technical analysis shows bearish market trends. Valuation remains speculative with a negative P/E ratio, emphasizing the high-risk nature of investing in developmental biotech firms.
Positive Factors
Clinical Results
Multiple doses of INB-200 showed mPFS of 16.1 months, beating historical benchmarks of 6.2 months and 10.3 months in GBM patients with unmethylated or methylated MGMT promoter, respectively.
Preclinical Data
IN8bio presented promising preclinical data with their CD19 targeting γδ TCE (INB-619) showing deep B cell depletion in blood samples from lupus patients.
Strategic Partnerships
Management is exploring partnership and collaboration options to further develop the program, indicating strategic growth opportunities.
Negative Factors
Financial Performance
Estimated fiscal year cash burn is projected to be higher than the current cash and cash equivalents.
Revenue and Earnings
The company reported no revenues and a net loss per share, in-line with consensus estimates.

IN8bio (INAB) vs. SPDR S&P 500 ETF (SPY)

IN8bio Business Overview & Revenue Model

Company DescriptionIN8bio, Inc. (NASDAQ: INAB) is a clinical-stage biotechnology company focused on developing innovative gamma-delta T cell therapies for the treatment of cancer. The company operates in the biotechnology and healthcare sectors, leveraging its proprietary technology platform to create cell-based immunotherapies aimed at targeting both solid tumors and hematologic malignancies. IN8bio's core products are designed to harness the power of the immune system to recognize and attack cancer cells, offering potential therapeutic options for patients with limited treatment alternatives.
How the Company Makes MoneyIN8bio generates revenue primarily through collaborations and strategic partnerships with other biotechnology and pharmaceutical companies. These partnerships involve licensing agreements, milestone payments, and royalties linked to the development and commercialization of its proprietary gamma-delta T cell therapies. Additionally, the company may receive funding from grants and research support from governmental agencies or non-profit organizations interested in advancing cancer immunotherapy research. As IN8bio progresses towards commercialization, revenue streams may also include direct sales of approved therapies, pending successful clinical trials and regulatory approvals.

IN8bio Financial Statement Overview

Summary
IN8bio's financial performance reflects a typical biotechnology company in the developmental stage, with a strong reliance on external funding due to non-existent revenues and substantial operational losses. While the company has managed to secure financing to support operations, the declining equity and significant negative cash flows present financial stability challenges in the long term.
Income Statement
15
Very Negative
IN8bio has consistently reported zero revenue over the years, which is typical for early-stage biotechnology firms that rely on funding rather than sales. The company has reported increasing net losses annually, with a net income of -$30.4 million in the most recent year, reflecting significant operational expenses and R&D costs.
Balance Sheet
30
Negative
The company's balance sheet shows a declining stockholders' equity from $38.2 million in 2021 to $14.5 million in 2024, indicating substantial use of equity to fund operations. The debt-to-equity ratio has increased, reflecting increased reliance on debt despite a relatively low total debt level. The equity ratio has also decreased, indicating a higher proportion of liabilities in the capital structure.
Cash Flow
20
Very Negative
IN8bio's cash flow statements reveal large negative free cash flows, primarily due to substantial operating cash outflows. The company has been relying heavily on financing activities to fund its operations, as seen in significant financing cash inflows. This pattern highlights potential liquidity risks if external financing becomes unavailable.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.000.00
Gross Profit-631.00K0.00-2.50M-1.10M-251.00K-96.00K
EBITDA-24.36M-27.78M-28.50M-27.42M-14.40M-8.47M
Net Income-27.43M-30.44M-30.01M-27.42M-14.65M-8.56M
Balance Sheet
Total Assets19.87M20.94M33.71M33.04M42.22M20.91M
Cash, Cash Equivalents and Short-Term Investments11.89M11.12M21.28M18.18M37.02M17.99M
Total Debt4.27M5.03M4.89M5.87M2.41M174.00K
Total Liabilities5.99M6.47M8.77M10.31M4.04M2.59M
Stockholders Equity13.88M14.48M24.94M22.73M38.18M18.32M
Cash Flow
Free Cash Flow-19.39M-24.25M-23.94M-27.83M-13.82M-7.13M
Operating Cash Flow-19.35M-24.15M-23.34M-24.12M-13.51M-7.13M
Investing Cash Flow-33.00K-187.00K-600.00K-3.71M-309.00K0.00
Financing Cash Flow18.35M14.18M27.04M8.99M32.95M24.52M

IN8bio Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.16
Price Trends
50DMA
3.80
Negative
100DMA
5.27
Negative
200DMA
7.04
Negative
Market Momentum
MACD
-0.51
Negative
RSI
29.97
Positive
STOCH
19.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INAB, the sentiment is Negative. The current price of 2.16 is below the 20-day moving average (MA) of 2.53, below the 50-day MA of 3.80, and below the 200-day MA of 7.04, indicating a bearish trend. The MACD of -0.51 indicates Negative momentum. The RSI at 29.97 is Positive, neither overbought nor oversold. The STOCH value of 19.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INAB.

IN8bio Risk Analysis

IN8bio disclosed 77 risk factors in its most recent earnings report. IN8bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

IN8bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
46
Neutral
$11.50M-83.92%-67.87%0.40%
46
Neutral
C$192.85M-4.28-8.56%2.83%13.52%-1.74%
42
Neutral
$16.35M-92.35%-85.48%45.13%
42
Neutral
$11.90M-76.12%81.71%
41
Neutral
$16.26M-397.54%24.16%
41
Neutral
$15.72M-89.73%-100.00%-292.59%
34
Underperform
$7.13M-174.66%38.53%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
INAB
IN8bio
2.16
-21.84
-91.00%
IMNN
Imunon
0.80
-0.56
-41.18%
MEIP
MEI Pharma
2.40
-0.40
-14.29%
PHIO
Phio Pharmaceuticals
2.48
-2.76
-52.67%
BOLT
Bolt Biotherapeutics
5.91
-8.51
-59.02%
SABS
SAB Biotherapeutics
1.75
-1.12
-39.02%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 22, 2025